TORONTO, ONTARIO--(Marketwired - Nov. 21, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced that Mr. Bernie Doyle will join the Company as a Technical Advisor to support the development of the Company's proposed proprietary patient-focused program enabled by blockchain and artificial intelligence ("AI") dedicated to the medical cannabis sector.
"I am pleased that Bernie has joined Revive to assist with the development of our proposed patient-focused solution driven by blockchain and artificial intelligence, that will provide licensed producers of medical cannabis and healthcare professionals unique tools and authentic information to support their objective of giving the highest possible quality of care to patients," said Fabio Chianelli, President of Revive. "Bernie has significant experience and knowledge in the field of software and blockchain development and design. He will be instrumental in assisting Revive's initiatives in the development of a novel technology solutions to support our future medical cannabis products, healthcare professionals and licensed producers of medical cannabis."
"I am very excited to be a part of the Revive team as we work to develop a one-of-a-kind technology solution for the medical cannabis sector," said Bernie Doyle, Blockchain Technical Advisor for the Company. "I am pleased to utilize my expertise to pave the way for a proprietary blockchain technology solution that will ultimately drive the development and the use of novel, safe, consistent, and effective cannabinoid-based therapeutics."
The potential of a patient-focused program enabled by blockchain and AI technology for the medical cannabis sector is significant. Blockchain technology unlocks the potential to ensure the security of shared information, such as clinical data and user data throughout the product lifecycle, and allows for the potential of personalized care by enabling patients, healthcare professionals, researchers and licensed producers of medical cannabis to collaborate, to innovate and develop medical cannabis products in treating specific medical disorders, and to deploy individualized cannabis-based therapies based on authentic evidence of use of proprietary medical cannabis products, which is an important aspect of cannabis treatment due to the various cannabis strains and ratios that can be produced to provide optimal care to patients.
Bernie Doyle is a Certified Ethereum Blockchain Developer and owner of Refine Labs, a blockchain advisory, architecture and development company, and he is currently president of the Government Blockchain Association - Toronto chapter. With nearly 10 years of software development experience, Mr. Doyle has been also dedicated in delivering advanced educational presentations on ground-breaking software and cloud-based solutions, blockchain, distributed ledger technology and smart contracts for a number of sectors, including fintech and healthcare. Mr. Doyle is a thought leader in the field of blockchain and he is dedicated to being a leader in connecting and educating government, organizations, businesses and individuals about blockchain, and he is focused on developing novel uses of blockchain to a variety of sectors.
About Revive Therapeutics Ltd.
Revive is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors. Additional information on Revive is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.
This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking information" that involves known and unknown risks and uncertainties, which are not comprised of historical facts, and most of which are beyond the control of Revive. Forward-looking statements include estimates and statements that describe Revive's future plans, objectives or goals, including words to the effect that Revive or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company's research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; the Company's drug research and development, and commercialization plans for blockchain and artificial intelligence; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect and no assurance can be given that such events will occur in the disclosed time frames or at all.
Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2017 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.